[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623402":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":11,"studyPopulation":11,"armGroups":30,"interventions":36,"overallOfficials":11,"centralContacts":42,"locations":48,"responsibleParty":65,"collaborators":11,"id":67,"slug":11,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":11,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":11,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":11,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"The Skin Center Dermatology Group","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":18},[9,13],{"measure":10,"description":11,"timeFrame":12},"Change from baseline at 24 weeks in Lichen Planopilaris Activity Index (LPPAI)",null,"24 weeks",{"measure":14,"description":11,"timeFrame":12},"Change from baseline at 24 weeks in Investigator Global Assessment (IGA) score (scarring alopecia version)",[16],{"measure":17,"description":11,"timeFrame":12},"Change from baseline at 24 weeks in Peak Pruritus NRS.",[19,21],{"measure":20,"description":11,"timeFrame":12},"Change from baseline at 24 weeks in hair count and average hair shaft thickness (digital trichoscopy).",{"measure":22,"description":11,"timeFrame":23},"Incidence and severity of treatment-emergent adverse events.","28 weeks",{"allocation":25,"interventionModel":26,"interventionModelDescription":11,"primaryPurpose":27,"observationalModel":11,"timePerspective":11,"maskingInfo":28},"NA","SINGLE_GROUP","TREATMENT",{"masking":29,"maskingDescription":11,"whoMasked":11},"NONE",[31],{"label":32,"type":33,"description":11,"interventionNames":34},"Patients receive nemolizumab injections every 4 weeks, weight based dosing","EXPERIMENTAL",[35],"Drug: Nemolizumab",[37],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"DRUG","Nemolizumab","subcutaneous injection",[32],[43],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Peter Friedman, MD PhD","CONTACT","8453520500","drfriedman@skincenterderm.com",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","New City","New York","10956","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-73.98931,41.1476,{"lat":60,"lon":59},[63],{"name":64,"role":45,"phone":46,"phoneExt":11,"email":47},"Peter C Friedman, MD PhD",{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623402",false,"NCT07396168","Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clinical and\u002For histopathologic diagnosis of LPP.\n* Presence of scalp pruritus.\n* Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.\n* Ability and willingness to provide written informed consent and comply with study procedures.\n* Willingness to undergo optional scalp biopsy for research purposes.\n\nExclusion Criteria:\n\n* Other forms of alopecia that may interfere with study assessments.\n* Any systemic disease associated with hair loss.\n* Inflammatory or infectious scalp disease that may interfere with the study.\n* Any other conditions associated with pruritus.\n* Prior use of nemolizumab.\n* Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).\n* Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).\n* Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or\n* biologics.\n* Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).\n* Any other current treatments for hair loss (e.g., oral\u002Ftopical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.\n* Allergy or hypersensitivity to nemolizumab or any excipients.\n* Pregnancy or unwillingness to use highly effective contraception.\n* Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.","ALL","18 Years",{"count":75,"type":76},10,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.",[82],"Lichen Plano-Pilaris","2026-02-07",{"date":85,"type":86},"2026-02-10","ACTUAL",{"date":88,"type":86},"2026-02-01",{"date":90,"type":76},"2027-06",{"name":5,"class":6},1]